Article Figures & Data
Figures
- Fig 1.
The PulseRider device is a self-expanding, nitinol implant that is fully retrievable and can be repositioned with radiopaque markers to aid in visibility during deployment and manipulation. The device is available in both Y- and T-configurations, as displayed, and has several different diameters and lengths available. The radiopaque markers are highlighted in red. Photograph provided courtesy of Cerenovus.
- Fig 2.
The PulseRider device is versatile and can be positioned with both wings within the daughter branches (A), 1 in a daughter branch and 1 in the aneurysm neck (B), or both within the aneurysm neck itself (C). The device is then traversed with the coiling microcatheter for coil embolization (D). Reprinted from Spiotta AM, Derdeyn CP, Tateshima S, et al. Results of the ANSWER trial using the PulseRider for the treatment of broad-necked, bifurcation aneurysms. Neurosurgery 2017;81(1):56–65, by permission of the Congress of Neurological Surgeons.
Tables
Angiographic aneurysm occlusions at treatment (day 0), day 180, and day 365
Raymond-Roy Score Aneurysm Occlusion (No.) (%) Day 0 (n = 34) Day 180a (n = 33) Day 365b (n = 30) I 18 (53%) 20 (61%) 20 (67%) II 9 (26%) 9 (27%) 7 (23%) III 7 (21%) 4 (12%) 3 (10%) I/II 27 (79%) 29 (88%) 27 (90%) ↵a Adequate occlusion was defined as Raymond-Roy I or II occlusion. One subject with a carotid terminus aneurysm had a CTA at 180 days, and occlusion data were not available on the image. The same subject died due to metastatic cancer before the 365-day visit and is not included in the 365-day data.
↵b Three subjects were lost to follow-up at the 365-day visit.
